Epiomic Epidemiology Series: Gaucher’s Disease Forecast in 30 Major Markets 2018–2028

June 2018 | 120 pages | ID: E1C6A4D7AB5EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Gaucher’s Disease in 30 Major Markets

Gaucher’s Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage.

This report provides the current prevalent population for GD across 30 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Greece, Romania, Slovenia, Czech Republic, Lithuania, Estonia, Russia, Turkey, Japan, China, South Korea, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the genotypes and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

• Splenomegaly
• Hepatomegaly
• Haematological conditions
• Musculoskeletal conditions
• Gall stones

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global GD market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on GD prevalent population.
• Examination of the prevalence of the different causative gene mutations for GD.
• Identify sub-populations within GD which require treatment.
• Gain an understanding of the specific markets that have the largest number of GD patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR GAUCHER’S DISEASE
FEATURES OF GAUCHER’S DISEASE PATIENTS
COMORBIDITIES OF GAUCHER’S DISEASE PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Characteristics of the three types of Gaucher’s disease
Table 2. Prevalence of Gaucher’s disease, total (000s)
Table 3. Prevalence of Gaucher’s disease, males (000s)
Table 4. Prevalence of Gaucher’s disease, females (000s)
Table 5. Patients with Gaucher's disease by type, total (000s)
Table 6. Patients with Gaucher's disease by history of splenectomy, total (000s)
Table 7. Patients with type I Gaucher's disease by genotype, total (000s)
Table 8. Patients with type I Gaucher's disease by polyneuropathy status, total (000s)
Table 9. Patients with type I Gaucher's disease by history of splenectomy, total (000s)
Table 10. Patients with type III Gaucher's disease by genotype, total (000s)
Table 11. Gaucher's disease patients with thrombocytopaenia, total (000s)
Table 12. Gaucher's disease patients with anaemia, total (000s)
Table 13. Gaucher's disease patients with bleeding tendencies, total (000s)
Table 14. Gaucher's disease patients with bone/joint pain, total (000s)
Table 15. Gaucher's disease patients with radiological bone disease, total (000s)
Table 16. Gaucher's disease patients with bone crisis, total (000s)
Table 17. Type I Gaucher's disease patients with gallstones, total (000s)
Table 18. Type I Gaucher's disease patients with thrombocytopaenia, total (000s)
Table 19. Type I Gaucher's disease patients with anaemia, total (000s)
Table 20. Type I Gaucher's disease patients with bleeding tendencies, total (000s)
Table 21. Type I Gaucher's disease patients with bone crisis, total (000s)
Table 22. Type I Gaucher's disease patients with radiological bone disease, total (000s)
Table 23. Type I Gaucher's disease patients with Erlenmeyer flask deformity, total (000s)
Table 24. Type I Gaucher's disease patients with osteopaenia, total (000s)
Table 25. Type I Gaucher's disease patients with marrow infiltration, total (000s)
Table 26. Type I Gaucher's disease patients with bone infarct, total (000s)
Table 27. Type I Gaucher's disease patients with avascular necrosis, total (000s)
Table 28. Type I Gaucher's disease patients with a history of fracture, total (000s)
Table 29. Type I Gaucher's disease patients with lytic lesions, total (000s)
Table 30. Type I Gaucher's disease patients with Parkinson's disease, total (000s)
Table 31. Abbreviations and acronyms used in the report
Table 32. USA prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 33. USA prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 34. Canada prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 35. Canada prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 36. France prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 37. France prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 38. Germany prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 39. Germany prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 40. Italy prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 41. Italy prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 42. Spain prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 43. Spain prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 44. UK prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 45. UK prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 46. Poland prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 47. Poland prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 48. Netherlands prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 49. Netherlands prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 50. Belgium prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 51. Belgium prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 52. Norway prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 53. Norway prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 54. Sweden prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 55. Sweden prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 56. Finland prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 57. Finland prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 58. Denmark prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 59. Denmark prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 60. Austria prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 61. Austria prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 62. Greece prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 63. Greece prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 64. Romania prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 65. Romania prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 66. Slovenia prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 67. Slovenia prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 68. Czech Republic prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 69. Czech Republic prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 70. Lithuania prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 71. Lithuania prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 72. Estonia prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 73. Estonia prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 74. Russia prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 75. Russia prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 76. Turkey prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 77. Turkey prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 78. Japan prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 79. Japan prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 80. China prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 81. China prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 82. South Korea prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 83. South Korea prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 84. India prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 85. India prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 86. Brazil prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 87. Brazil prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 88. Mexico prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 89. Mexico prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Table 90. Argentina prevalence of Gaucher’s disease by 5-yr age cohort, males (000s)
Table 91. Argentina prevalence of Gaucher’s disease by 5-yr age cohort, females (000s)
Figure 1. Incidence of type I Gaucher’s disease by age